Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 187

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Comprehensive Platform for Ex Vivo T-cell Expansion Based on Biodegradable Polymeric Artificial Antigen-presenting Cells

Open access
Steenblock, Erin R, Fahmy, Tarek M·2008·Molecular Therapy
DOI 10.1038/mt.2008.11
Open this paper in CoChat — free account

Abstract

Efficient T-cell stimulation and proliferation in response to specific antigens is a goal of immunotherapy against infectious disease and cancer. Manipulation of this response can be accomplished by adoptive immunotherapy involving the infusion of antigen-specific T-cell populations expanded ex vivo with antigen presenting cells. We mimicked physiological antigen presentation on a biodegradable microparticle constructed from poly(lactide-co-glycolide) (PLGA), a polymer system whose safety has been established for use in humans. These particles present a high density of adaptor elements for attaching both recognition ligands and co-stimulatory ligands to a biodegradable core encapsulating the cytokine interleukin-2 (IL-2). We demonstrate the utility of this system in efficient polyclonal and antigen-specific T-cell stimulation and expansion, showing that sustained release of IL-2 in the vicinity of T-cell contacts dramatically improves the stimulatory capacity of these acellular systems, as compared to the effect of exogenous addition of cytokine. This results in a 45-fold enhancement in T-cell expansion. In addition, this mode of antigen presentation skews the expansion toward the CD8(+) T-cell phenotype. This comprehensive acellular platform, capable of delivering recognition, co-stimulatory, and cytokine signals, represents a promising new technology for artificial antigen presentation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2008.11

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 44

  1. Papadopoulos, 1994, Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation, N Engl J Med, 330, 1185, 10.1056/NEJM199404283301703 · DOI · Paper page
  2. Savoldo, 2000, The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients, Leuk Lymphoma, 39, 455, 10.3109/10428190009113376 · DOI
  3. Hori, 2003, Control of autoimmunity by naturally arising regulatory CD4+ T cells, Adv Immunol, 81, 331, 10.1016/S0065-2776(03)81008-8 · DOI · Paper page
  4. Karim, 2004, Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process, J Immunol, 172, 923, 10.4049/jimmunol.172.2.923 · DOI · Paper page
  5. Dudley, 2003, Adoptive-cell-transfer therapy for the treatment of patients with cancer, Nat Rev Cancer, 3, 666, 10.1038/nrc1167 · DOI · Paper page
  6. Riddell, 2002, T-cell therapy of leukemia, Cancer Control, 9, 114, 10.1177/107327480200900204 · DOI
  7. Yee, 2002, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc Natl Acad Sci USA, 99, 16168, 10.1073/pnas.242600099 · DOI · Paper page
  8. Oelke, 2003, Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells, Nat Med, 9, 619, 10.1038/nm869 · DOI · Paper page
  9. Kim, 2004, The ABCs of artificial antigen presentation, Nat Biotechnol, 22, 403, 10.1038/nbt955 · DOI · Paper page
  10. Hirano, 2006, Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses, Clin Cancer Res, 12, 2967, 10.1158/1078-0432.CCR-05-2791 · DOI
  11. Maus, 2002, Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB, Nat Biotechnol, 20, 143, 10.1038/nbt0202-143 · DOI · Paper page
  12. Mitchell, 2002, Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope, J Clin Oncol, 20, 1075, 10.1200/JCO.20.4.1075 · doi:10.1200/jco.20.4.1075
  13. Jackson, 1992, Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells, Proc Natl Acad Sci USA, 89, 12117, 10.1073/pnas.89.24.12117 · DOI
  14. Sun, 1996, Dual function of Drosophila cells as APCs for naive CD8+ T cells: implications for tumor immunotherapy, Immunity, 4, 555, 10.1016/S1074-7613(00)80482-3 · DOI
  15. Latouche, 2000, Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells, Nat Biotechnol, 18, 405, 10.1038/74455 · DOI · Paper page
  16. Schoenberger, 1998, Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC, Cancer Res, 58, 3094
  17. Levine, 1996, Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation, Science, 272, 1939, 10.1126/science.272.5270.1939 · DOI · Paper page
  18. Tham, 2001, Activation of antigen-specific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-Fc proteins, J Immunol Methods, 249, 111, 10.1016/S0022-1759(00)00335-5 · DOI
  19. Shalaby, 2004, Absorbable microparticulate cation exchanger for immunotherapeutic delivery, J Biomed Mater Res B Appl Biomater, 69, 173, 10.1002/jbm.b.20040 · DOI
  20. van Rensen, 1999, Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation, Pharm Res, 16, 198, 10.1023/A:1018864005620 · doi:10.1023/a:1018864005620
  21. Prakken, 2000, Artificial antigen-presenting cells as a tool to exploit the immune “synapse”, Nat Med, 6, 1406, 10.1038/82231 · DOI
  22. Thery, 2002, Exosomes: composition, biogenesis and function, Nat Rev Immunol, 2, 569, 10.1038/nri855 · DOI · Paper page
  23. Pardoll, 2002, Spinning molecular immunology into successful immunotherapy, Nat Rev Immunol, 2, 227, 10.1038/nri774 · DOI · Paper page
  24. Fyfe, 1995, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J Clin Oncol, 13, 688, 10.1200/JCO.1995.13.3.688 · DOI · Paper page
  25. Schluns, 2003, Cytokine control of memory T-cell development and survival, Nat Rev Immunol, 3, 269, 10.1038/nri1052 · DOI · Paper page
  26. Riddell, 2007, Engineering antitumor immunity by T-cell adoptive immunotherapy, Hematology Am Soc Hematol Educ Program, 250, 10.1182/asheducation-2007.1.250 · DOI
  27. Yamaguchi, 1993, In vivo biocompatibility studies of medisorb(R) 65/35 D, L-lactide/glycolide copolymer microspheres, J Control Release, 24, 81, 10.1016/0168-3659(93)90169-6 · DOI
  28. Fahmy, 2005, Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting, Biomaterials, 26, 5727, 10.1016/j.biomaterials.2005.02.025 · DOI · Paper page
  29. Mahoney, 2001, Transplantation of brain cells assembled around a programmable synthetic microenvironment, Nat Biotechnol, 19, 934, 10.1038/nbt1001-934 · DOI
  30. Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials, 21, 2475, 10.1016/S0142-9612(00)00115-0 · DOI · Paper page
  31. Hogquist, 1994, T cell receptor antagonist peptides induce positive selection, Cell, 76, 17, 10.1016/0092-8674(94)90169-4 · DOI · Paper page
  32. MacGlashan, 1985, Test of a theory relating to the cross-linking of IgE antibody on the surface of human basophils, J Immunol, 135, 4129, 10.4049/jimmunol.135.6.4129 · doi:10.4049/jimmunol.135.6.4129
  33. Stone, 2001, T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model, Biophys J, 81, 2547, 10.1016/S0006-3495(01)75899-7 · DOI
  34. Fahmy, 2001, Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen, Immunity, 14, 135
  35. Mescher, 1992, Surface contact requirements for activation of cytotoxic T lymphocytes, J Immunol, 149, 2402, 10.4049/jimmunol.149.7.2402 · DOI
  36. Deeths, 1997, B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells, Eur J Immunol, 27, 598, 10.1002/eji.1830270305 · DOI
  37. van de Weert, 2000, Protein instability in poly(lactic-co-glycolic acid) microparticles, Pharm Res, 17, 1159, 10.1023/A:1026498209874 · DOI · Paper page
  38. Cohen, 1991, Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres, Pharm Res, 8, 713, 10.1023/A:1015841715384 · DOI · Paper page
  39. Garlie, 1999, T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer, J Immunother, 22, 336, 10.1097/00002371-199907000-00007 · doi:10.1097/00002371-199907000-00007
  40. Gattinoni, 2005, Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells, J Clin Invest, 115, 1616, 10.1172/JCI24480 · DOI · Paper page
  41. Oelke, 2005, Artificial antigen-presenting cells: artificial solutions for real diseases, Trends Mol Med, 11, 412, 10.1016/j.molmed.2005.07.005 · DOI
  42. Gopferich, 1996, Mechanisms of polymer degradation and erosion, Biomaterials, 17, 103, 10.1016/0142-9612(96)85755-3 · DOI · Paper page
  43. Boyman, 2006, Selective stimulation of T cell subsets with antibody-cytokine immune complexes, Science, 311, 1924, 10.1126/science.1122927 · DOI · Paper page
  44. Scheffold, 2007, Competition for cytokines: T(reg) cells take all, Nat Immunol, 8, 1285, 10.1038/ni1207-1285 · DOI

Cited by

See all 187

Metadata

Authors
Steenblock, E. R., & Fahmy, T. M.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2008-04
Volume
16
Issue
4
Pages
765-772
ISSN
1525-0016 (ISSN-L)
DOI
10.1038/mt.2008.11
OpenAlex
W1976027404
Cited by
187
References
2
FWCI
2.54
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Comprehensive Platform for Ex Vivo T-cell Expansion Based on Biodegradable Polymeric Artificial Antigen-presenting Cells. https://app.cochat.ai/papers/10.1038/mt.2008.11
The paper
Steenblock, E. R., & Fahmy, T. M. (2008). A Comprehensive Platform for Ex Vivo T-cell Expansion Based on Biodegradable Polymeric Artificial Antigen-presenting Cells. Molecular Therapy. https://doi.org/10.1038/mt.2008.11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.